MRN:______________________

DOB:____________________

STANDARD SAPHNELO® (Anifrolumab-fnia) PLAN OF TREATMENT

NOTE: Patient ***may be ineligible*** to receive Anifrolumab-fnia if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, and/or surgery.

1. Patient Name:______________________________________Height (inches):_____Weight (lbs):_____

2. Allergies:____

3. Diagnosis: ☐ **M32.90 Systemic lupus erythematosus, unspecified**

☐ Other **ICD-10 Code:**________**Diagnosis description:** ______________________________________

4. Pre-medications: ***Administered 30 minutes prior to infusion as selected***

Acetaminophen:	Diphenhydramine: □ 25 mg PO, □ 50 mg PO, □ 25 mg IVP, □ 50 mg IVP or
□ 650 mg PO	Fexofenadine □ 60mg or □ 180 mg, □ Cetirizine 10 mg, □ Loratadine 10 mg
□ 500 mg PO	Methylprednisolone □ 40 mg IVP □ 125 mg IVP or other______mg IVP
□ 325 mg PO	Famotidine: □ 20 mg PO, □ 40 mg PO, □ 20 mg IVP, □ 40 mg IVP

Pre-medicate with other: ____

CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion

Orders: Saphnelo® (Anifrolumab-fnia) 300mg per 100 ml Sodium Chloride 0.9% IV to infuse over 30 minutes every 4 weeks via pump with 0.2 or 0.22-micron filter.

Upon completion of the infusion, Flush the infusion set with 25mL of 0.9% Sodium Chloride Injection, USP

Special Orders: ____

If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES

5. Physician's Signature:________________________/________________________Date: _______________

No Stamp Signatures (Dispense as written) (Substitution permitted)

Printed Physician's Name with Credentials:____NPI: ____________________

6. Fax updated supporting clinical MD notes with each order renewal or change in orders

Revised 08/12/21

MRN:______________________

DOB:______________________

Guidelines for Prescribing SAPHNELO® (Anifrolumab-fnia)

(Required documentation with all initial referrals)

Patient Name: ____ **Referral Date:**____________________

___ Include signed and completed **Plan of Treatment**. *(MD must complete sections 1-)*
(Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

___ Include patient demographic information and insurance information. (Copy of insurance cards if available)

___ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

___ Other as requested: ____

____

____

** Warnings/Precautions: **Serious Infections:** Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including Saophnelo®. Use with caution in patients with severe or chronic infections. Consider interrupting therapy with Saophnelo® if patients develop a new infection during treatment. **Hypersensitivity Reactions including anaphylaxis** and events of Angioedema have been reported. Consider pre-medication before infusion of Saphnelo for a patient with history of these reactions**.** **Malignancy** There is an increased risk of Malignancy with use of Immunosuppressants. The impact of Saphnelo treatment on the potential development of malignancy is unknown.

Limitations of Use: The efficacy of Saophnelo® has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Saphnelo® has not been studied in combination with other biologics. Use of BENLYSTA® is not recommended in these situations.

Evaluation of immunizations should be completed prior to, and live vaccines should not be given for 30 days before or concurrently with Saophnelo®. See full prescribing information

Checklist for referrals to AccuRX Infusion Center:

Fax referral to 1-866-990-3192

- Patient demographics – address, phone number, SS#, etc.
- Insurance Information – copy of the card(s) if possible
- Plan of Treatment/Orders
- Most recent physician office notes to include tried and failed therapies – all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs
- Any lab results or other diagnostic procedures to support the diagnosis

AccuRx Infusion Center will complete insurance verification and submit all required clinical documentation to the patient’s insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.